<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379024</url>
  </required_header>
  <id_info>
    <org_study_id>Study00145121</org_study_id>
    <nct_id>NCT04379024</nct_id>
  </id_info>
  <brief_title>Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms</brief_title>
  <official_title>Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms at Increased Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carol Fabian, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study to test feasibility of 6 months of Duavee® vs wait-list control in&#xD;
      post-menopausal women symptomatic for hot flashes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duavee® which is the combination of the selective estrogen receptor modulator bazedoxifene&#xD;
      and conjugated estrogen 0.45 mg) is an FDA approved drug for treatment of hot-flashes and&#xD;
      prevention of osteoporosis in postmenopausal women. The investigators recently reported the&#xD;
      results of a single arm pilot study suggesting that 6 months of Duavee® was associated with&#xD;
      improvement in several risk biomarkers including benign breast tissue proliferation,&#xD;
      mammographic fibroglandular volume, IGF-1, SHBG and progesterone in high risk women in late&#xD;
      menopause transition. Prior to opening a randomized Phase IIB trial of 6 months of Duavee® vs&#xD;
      placebo in high risk women with hot-flashes followed by open label Duavee®, the intent of&#xD;
      this study is to assess probable uptake of such a trial design with a pilot of 6 months of&#xD;
      Duavee® vs wait-list control in symptomatic women. Additional imaging biomarker information&#xD;
      from MRI will be obtained. A finding on MRI of greater background parenchymal enhancement&#xD;
      (BPE) in high risk women is positively associated with higher probability of developing&#xD;
      breast cancer and is independent of fibroglandular volume. BPE is reduced by selective&#xD;
      estrogen receptor modulators including tamoxifen. The investigators will investigate change&#xD;
      in MRI BPE over time for women randomly assigned to either receive Duavee® or not (wait-list&#xD;
      control). The investigators will also explore development of fully automated breast MRI&#xD;
      volumetric density measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study agent no longer available&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized to active agent or wait-list control.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Randomization assignment is masked to all roles prior to randomization. Subsequent to randomization, agent is dispensed open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of potential participants who consent to enrollment</measure>
    <time_frame>Enrollment</time_frame>
    <description>Trial design is acceptable to potential subjects, as evidenced by participation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in breast background parenchymal enhancement (BPE)</measure>
    <time_frame>6 months</time_frame>
    <description>BPE assessed by abbreviated MRI at baseline and after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibroglandular volume (FGV)</measure>
    <time_frame>6 months</time_frame>
    <description>FGV assessed by Volpara software on 3D mammograms acquired at baseline and after 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Focus of Study is Healthy Women at Risk for Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Immediate active agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duavee. One capsule daily for 6 months (+/- 1 month) of Duavee (Bazedoxifene 20 mg plus conjugated estrogens 0.45 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed active agent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No intervention for first 6 months. Then option to receive daily Duavee for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DUAVEE 0.45Mg-20Mg Tablet</intervention_name>
    <description>One capsule daily for 6 months (+/- 1 month)</description>
    <arm_group_label>Delayed active agent</arm_group_label>
    <arm_group_label>Immediate active agent</arm_group_label>
    <other_name>Bazedoxifene 20 mg plus conjugated estrogens 0.45 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who report vasomotor symptoms (hot flashes or night sweats)&#xD;
&#xD;
          -  No menstrual periods for at least 3 months&#xD;
&#xD;
          -  Must have at least one ovary (hysterectomy is permitted; bilateral salpingo-&#xD;
             oophorectomy is excluded).&#xD;
&#xD;
          -  BMI &lt;36 kg/m2&#xD;
&#xD;
          -  Moderate risk of developing breast cancer based on having any one or more of the&#xD;
             following:&#xD;
&#xD;
               -  First or 2nd degree relative with breast cancer&#xD;
&#xD;
               -  Known carrier of moderate to high penetrance germline mutation&#xD;
&#xD;
               -  Prior breast biopsy showing proliferative breast disease or multiple biopsies&#xD;
&#xD;
               -  High mammographic density (Volpara® categories c or d or BIRADs density&#xD;
                  assessment as heterogeneously or extremely dense (c or d).&#xD;
&#xD;
               -  IBIS Breast Cancer Risk Evaluation Version 8 10-year relative risk of &gt;2X that&#xD;
                  for the population for age group.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Risk: A prior biopsy showing LCIS, DCIS, or invasive breast cancer.&#xD;
&#xD;
          -  Medical Conditions:&#xD;
&#xD;
               -  Have a predisposition to or prior history of thromboembolism, deep venous&#xD;
                  thrombosis, pulmonary embolism, or stroke&#xD;
&#xD;
               -  History of renal or liver disease&#xD;
&#xD;
               -  Prior invasive ovarian or endometrial cancer&#xD;
&#xD;
          -  Medications&#xD;
&#xD;
               -  Current anticoagulant use other than low dose aspirin&#xD;
&#xD;
               -  Taking systemic hormones within two months (eight weeks) prior to baseline MRI&#xD;
                  and mammogram.&#xD;
&#xD;
               -  Taking tamoxifen, raloxifene, Duavee, or any selective estrogen receptor&#xD;
                  modulator, or an aromatase inhibitor within 12 months prior to baseline MRI and&#xD;
                  mammogram.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol J Fabian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fabian CJ, Nye L, Powers KR, Nydegger JL, Kreutzjans AL, Phillips TA, Metheny T, Winblad O, Zalles CM, Hagan CR, Goodman ML, Gajewski BJ, Koestler DC, Chalise P, Kimler BF. Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study. Cancer Prev Res (Phila). 2019 Oct;12(10):711-720. doi: 10.1158/1940-6207.CAPR-19-0315. Epub 2019 Aug 16.</citation>
    <PMID>31420361</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Carol Fabian, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Imaging</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bazedoxifene</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

